Uniqure N.V. - (QURE) closed at $23.81 on November 13, 2026, down 3.3% from the previous close, on volume of 1,312,823 shares (30-day average 2,000,083).
Data as of November 13, 2026.
13-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 4, 2026 | Call Butterfly | 21-Jan-2845 : 50[2x] : 55 C | 1,580 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the 10 largest for 30, 60 and 90 days
TipRanks (Wed, 11-Nov 5:53 AM ET)
Market Chameleon (Wed, 4-Nov 3:26 AM ET)
uniQure Announces Third Quarter 2026 Financial Results and Provides Company Update
Globe Newswire (Wed, 4-Nov 7:05 AM ET)
Globe Newswire (Mon, 2-Nov 7:05 AM ET)
uniQure to Announce Third Quarter 2026 Financial Results
Globe Newswire (Wed, 28-Oct 7:05 AM ET)
Newsfile (Tue, 13-Oct 7:12 PM ET)
Business Wire (Tue, 6-Oct 6:00 PM ET)
Globe Newswire (Wed, 30-Sep 6:43 PM ET)
PRNewswire (Tue, 29-Sep 8:12 PM ET)
QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with SBS Law
Business Wire (Tue, 29-Sep 1:28 PM ET)
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
Uniqure N.V. - trades on the NASDAQ stock market under the symbol QURE.
As of November 13, 2026, QURE stock price declined to $23.81 with 1,312,823 million shares trading.
QURE has a beta of 3.67, meaning it tends to be more sensitive to market movements. QURE has a correlation of 0.11 to the broad based SPY ETF.
QURE has a market cap of $1.67 billion. This is considered a Small Cap stock.
Last quarter Uniqure N.V. - reported $5 million in Revenue and -$.88 earnings per share. This fell short of revenue expectation by $-573,200 and missed earnings estimates by -$.06.
In the last 3 years, QURE traded as high as $71.50 and as low as $3.73.
The top ETF exchange traded funds that QURE belongs to (by Net Assets): XBI, VXF, IBB, JGRO, SCHA.
QURE has underperformed the market in the last year with a price return of -21.5% while the SPY ETF gained +13.4%. QURE has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -49.4% and -4.1%, respectively, while the SPY returned -2.8% and -0.2%, respectively.
QURE support price is $23.20 and resistance is $26.06 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that QURE shares will trade within this expected range on the day.
